Adults 18 to 80, any sex, with Crohn's Disease or Abdominal Pain. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Primary· Up to approximately 12 weeks
TEAE was defined as an adverse event (AE) that occurred after first dose of olorinab. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events. Safety was assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
TEAEs
Group
Value
95% CI
Olorinab 25 mg TID
4
Olorinab 100 mg TID
6
SAEs
Group
Value
95% CI
Olorinab 25 mg TID
0
Olorinab 100 mg TID
1
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to approximately 12 weeks.
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this randomized, open-label, parallel, phase 2a study is to determine the tolerability, pharmacokinetics, and efficacy of olorinab in participants with Crohn's disease experiencing abdominal pain.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04655599 — Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
· Phase 1
· terminated
NCT04043455 — Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant
· Phase 2
· terminated
Other recruiting trials for Crohn's Disease
Currently open trials in the same condition.
NCT07273188 — 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
· EARLY_PHASE1
· recruiting
NCT07184944 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti
· Phase 3
· recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea
· recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD
· Phase 3
· recruiting
NCT07184931 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ
· Phase 3
· recruiting
Other Arena Pharmaceuticals trials
Trials by the same sponsor.
NCT04655599 — Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
· Phase 1
· terminated
NCT03996369 — Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
· Phase 3
· completed
NCT04162769 — A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
· Phase 2
· completed
NCT04043455 — Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant
· Phase 2
· terminated
NCT03945188 — Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
· Phase 3
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arena Pharmaceuticals
Last refreshed: 2 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03155945.